跳至主要内容
临床试验/NCT03249220
NCT03249220进行中(未招募)不适用

Clinical Pilot Study to Evaluate a New Multi-parameter Neuromonitoring Device That Allows the Measurement of Regional Cerebral Blood Flow (rCBF), Intracranial Pressure (ICP), Brain Temperature Monitoring and Ventricular Cerebrospinal Fluid (CSF) Drainage in Brain-injured Patients

Carag AG4 个研究点 分布在 1 个国家目标入组 1 人开始时间: 2020年9月1日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
1
试验地点
4
主要终点
Feasibility: Comparability of regional CBF values and values obtained with CT perfusion and TCD

研究概览

简要总结

Clinical pilot study to evaluate a new multi-parameter neuromonitoring device that allows the measurement of regional cerebral blood flow (rCBF), intracranial pressure (ICP), brain temperature monitoring and ventricular cerebrospinal fluid (CSF) drainage in brain-injured patients.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Device Feasibility
盲法
None

入排标准

年龄范围
18 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adult male or female patient, aged 18 - 75 years
  • Brain injured patients with acute intracranial hemorrhage (including aneurysmal subarachnoid hemorrhage (SAH) and spontaneous intracerebral hemorrhage (ICH)) who are admitted to the ICU and have an indication for ICP monitoring and CSF drainage, as per standard patient care
  • Informed consent obtained for research in emergency situations according to HRA art. 30 & 31 at time of inclusion

排除标准

  • Known kidney disease, defined as plasma creatinine > 120 μmol/l
  • Known liver disease, defined as AST > 200 IU/L
  • Over-active thyroid or benign tumors of the thyroid
  • History of allergic disorders, including allergic reactions, against contrast agents containing iodine, or against ICG
  • Patients which have received one of the following medications before being admitted to ICU: Haloperidol, Meperidine, Methadone, Morphine, Phenobarbital and Rifamycin.
  • Patients with wounds or scars including the front orbital region.
  • Cerebrospinal fluid infection or signs of meningo-encephalitis
  • Anemia (hemoglobin < 10 g/dl) or Thalassemia
  • Carbon monoxide poisoning
  • Acquired pathological or congenital disorders of the cerebral system, being clinically significant, respectively interfering in the investigator's opinion with the conduct of study
  • Documented history of bleeding, clotting or coagulation disorders
  • Patients who are not suitable for a CT perfusion
  • Subjects who, in the opinion of the investigator, will be inappropriate for inclusion into this clinical investigation or will not comply with requirements of the study
  • Any disorder in the investigator's opinion that could interfere with compliance of safety evaluation
  • Pre-existing disability and/or legal representative
  • Patients who are kept lawfully in an institution
  • Participation in another interventional clinical investigation within the last 30 days before start of treatment
  • History of, respectively diagnosis of pregnancy, or breastfeeding patients

结局指标

主要结局

Feasibility: Comparability of regional CBF values and values obtained with CT perfusion and TCD

时间窗: Up to 28 days until probe removal

Regional CBF values calculated with the investigational devices (CBMS) are within ranges described in literature, and dynamic changes of regional CBF are consistent to those values obtained with established methods CT perfusion and TCD.

次要结局

  • Safety related to catheter insertion and monitoring(Until 7 days after probe removal)

研究者

发起方
Carag AG
申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验